Top M3541 Secrets
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage several intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important demo goals were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyo